Atomwise takes on 2 more JVs, including a $1.5B project with China's Hansoh Pharma

People shaking hands across a desk that has computer and papers on it
Atomwise will also work with Atropos Therapeutics to develop a pipeline of senescence-focused cancer treatments. (Pixabay)

When it rains, it pours: Following two new joint ventures, artificial-intelligence-based drug designer Atomwise has announced two more projects in quick succession—including one with a Chinese biopharma company it says could net the company up to $1.5 billion for developing first-in-class molecules. 

The collaboration with Hansoh Pharma, Atomwise’s first partner in Asia, aims to design new drug candidates for up to 11 undisclosed protein targets in different disease areas.  

Atomwise’s scientific teams in AI technology, medicinal chemistry and protein structure will work closely with Hansoh’s R&D, manufacturing and commercial staff, according to the two companies. In return, Atomwise will receive undisclosed technology access fees as well as option exercise fees and royalty payments. 

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

RELATED: Atomwise inks 2 joint ventures in AI-based cancer drug development 

Meanwhile, Atomwise will work with California-based startup Atropos Therapeutics to develop a pipeline of cancer treatments.  

Atropos focuses on modulating cellular senescence, the regulated biological process that halts cell division and contributes to a normal part of aging. The failure and induction of senescence has also been linked to the progression of certain cancers.  

“This partnership with Atropos is an opportunity to ultimately provide patients with a fundamentally different class of drugs,” Atomwise co-founder and CEO Abraham Heifets, Ph.D., said in a statement

Under the agreement, the new joint venture company will be able to access tech from both Atropos and Atomwise to build out a new platform that screens compounds against anticancer targets. 

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.